209 related articles for article (PubMed ID: 20884430)
1. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
[TBL] [Abstract][Full Text] [Related]
4. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
5. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
6. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
Ito H; Hermiller JB; Yaqub M; Newman W; Sood P; Wang JC; Cannon L; Maddux JE; Sudhir K; Stone GW
J Interv Cardiol; 2011 Dec; 24(6):505-13. PubMed ID: 21919955
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
Stone GW; Rizvi A; Sudhir K; Newman W; Applegate RJ; Cannon LA; Maddux JT; Cutlip DE; Simonton CA; Sood P; Kereiakes DJ;
J Am Coll Cardiol; 2011 Jun; 58(1):19-25. PubMed ID: 21514084
[TBL] [Abstract][Full Text] [Related]
8. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).
Ng VG; Lansky AJ; Hermiller JB; Farhat N; Applegate RJ; Yaqub M; Sood P; Su X; Simonton CA; Sudhir K; Stone GW
Am J Cardiol; 2011 Mar; 107(6):841-8. PubMed ID: 21255760
[TBL] [Abstract][Full Text] [Related]
9. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
[TBL] [Abstract][Full Text] [Related]
10. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).
Smits PC; Kedhi E; Royaards KJ; Joesoef KS; Wassing J; Rademaker-Havinga TA; McFadden E
J Am Coll Cardiol; 2011 Jun; 58(1):11-8. PubMed ID: 21514083
[TBL] [Abstract][Full Text] [Related]
11. Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial.
Garg S; Serruys PW; Miquel-Hebert K;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1012-7. PubMed ID: 20824770
[TBL] [Abstract][Full Text] [Related]
12. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
[TBL] [Abstract][Full Text] [Related]
13. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
Räber L; Wohlwend L; Wigger M; Togni M; Wandel S; Wenaweser P; Cook S; Moschovitis A; Vogel R; Kalesan B; Seiler C; Eberli F; Lüscher TF; Meier B; Jüni P; Windecker S
Circulation; 2011 Jun; 123(24):2819-28, 6 p following 2828. PubMed ID: 21646500
[TBL] [Abstract][Full Text] [Related]
14. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
[TBL] [Abstract][Full Text] [Related]
15. Current status of the Xience V® everolimus-eluting coronary stent system.
Claessen BE; Caixeta A; Henriques JP; Piek JJ
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
[TBL] [Abstract][Full Text] [Related]
16. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
Onuma Y; Miquel-Hebert K; Serruys PW;
EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
[TBL] [Abstract][Full Text] [Related]
17. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials.
Kedhi E; Stone GW
Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1207-10. PubMed ID: 20828341
[No Abstract] [Full Text] [Related]
19. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).
Biondi-Zoccai G; Lotrionte M; Moretti C; Agostoni P; Sillano D; Laudito A; Sheiban I
Minerva Cardioangiol; 2008 Feb; 56(1):55-65. PubMed ID: 18432169
[TBL] [Abstract][Full Text] [Related]
20. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
Beijk MA; Piek JJ
Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
